[SCHEDULE 13D/A] Camp4 Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

Camp4 Therapeutics Schedule 13D/A reports that Enavate Sciences GP, LLC and Everest Aggregator, LP each beneficially own 3,785,802 shares of Camp4 common stock, representing 8.1% of the class after a private placement. The amendment states the reported percentage is calculated using 20,161,073 shares outstanding as of August 5, 2025 plus 26,717,414 shares issued in a private placement that closed September 11, 2025. The filing clarifies that the change in reported percentage is due to dilution from the new issuance, not purchases or sales by the reporting persons, and discloses that James P. Boylan resigned from Camp4’s board effective September 9, 2025.

Insights

Financial Analyst

TL;DR: Ownership diluted to 8.1% after a private placement; no purchases or sales by reporting persons in prior 60 days.

The Schedule 13D/A updates beneficial ownership for Enavate Sciences GP and Everest Aggregator to 3,785,802 shares (8.1%) following a material equity issuance that increased the company’s share count. The filing confirms the holders did not transact in the prior 60 days and attributes the percentage change solely to dilution from the private placement of 26,717,414 shares. For investors, this is a disclosure-driven update rather than an active accumulation or disposition signal; the absolute stake remains unchanged while relative ownership declined.

Corporate Governance Expert

TL;DR: Director resignation and dilution are material governance developments that reduce reporting persons' board influence.

James P. Boylan’s resignation from the issuer’s board effective September 9, 2025 is a concrete governance change disclosed in this amendment. Combined with the dilution to an 8.1% stake, these facts reduce the reporting parties’ relative voting power and potential board influence. The filing contains no indication of related agreements or new rights, and it expressly states no other parties have rights to dividends or proceeds from these shares.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

CAMP4 THERAPEUTICS CORPORATION

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

13463J101

(CUSIP Number)

James P. Boylan
Enavate Sciences, 106 W 56th Street, 8th Floor
New York, NY, 10019
(332) 275-5551

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/11/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Enavate Sciences GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,785,802.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,785,802.00

11

Aggregate amount beneficially owned by each reporting person

3,785,802.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 13463J101

1

Name of reporting person

Everest Aggregator, LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,785,802.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,785,802.00

11

Aggregate amount beneficially owned by each reporting person

3,785,802.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, $0.0001 par value per share
(b)	Name of Issuer: CAMP4 THERAPEUTICS CORPORATION
(c)	Address of Issuer's Principal Executive Offices: One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MASSACHUSETTS , 02139.
Item 1 Comment: This Amendment No. 1 (this "Amendment No. 1" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on October 22, 2024 (the "Statement") by the Reporting Entities. This Amendment No. 1 is being filed to report the dilution of the Reporting Persons' beneficial ownership in the Issuer's Common Stock and not as a result of any acquisition or disposition of securities by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 1 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
Item 4.	Purpose of Transaction
	Item 4 of the Statement is amended and supplemented as follows: Effective September 9, 2025, James P. Boylan resigned from the Board of Directors of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	Rows 11 and 13 of each Reporting Entities' cover page to this Schedule 13D/A set forth the aggregate number of shares of Common Stock and percentages of the shares of Common Stock beneficially owned by such Reporting Entity and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 20,161,073 shares of Common Stock outstanding as of August 5, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 14, 2025 and (ii) 26,717,414 shares of Common Stock issued in the private placement of equity securities by the Issuer that closed on September 11, 2025. Everest LP directly holds 3,785,802 shares of Common Stock. Enavate GP is the general partner of Everest LP and shares voting and investment authority over the shares held by Everest LP.
(b)	Rows 7 through 10 of each Reporting Entities' cover page to this Schedule 13D/A set forth the number of shares of Common Stock as to which such Reporting Entity has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
(c)	No transactions with respect to the securities of the Issuer have been effected during the past sixty days by any Reporting Person. The percentage ownership reported in this amendment reflect an increase in the number of outstanding shares of the Issuer.
(d)	No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Common Stock.
(e)	Not applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13D filed with the SEC on October 22, 2024).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Enavate Sciences GP, LLC

Signature:	/s/ James P. Boylan
Name/Title:	By James P. Boylan, Manager
Date:	09/15/2025

Everest Aggregator, LP

Signature:	/s/ James P. Boylan
Name/Title:	By: Enavate Sciences GP, LLC, its General Partner, By James P. Boylan, Manager
Date:	09/15/2025